Moderna, Inc. MRNA
198.88
4.06
2.08%
as of 25 Sep
- Market cap
- $78.8B
- P/E
- 0.0×
Follow MRNA
Indexes
indicate stock being part of an index
Moderna, Inc. (MRNA) P/E ratio
Moderna, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 161× (June 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 8.5× | 0.99% |
| FY2021 | 8.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 30 more quarters | Free account |
Against its own ten years
Low 0.0×
High 161×
Ten-year median
0.0×
Current reading's percentile
68
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| INSM Insmed, Inc. compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| MRNA Moderna, Inc. | n/m |
| REGN Regeneron Pharmaceuticals, Inc. compare | 18.8× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 30.4× |
| ARGX argenex SE compare | 34.6× |
| RPRX Royalty Pharma PLC compare | 40.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 43.6× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 61.2× |
| Biotechnology industry median | 7.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on MRNA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement